Rubicon Research Ltd.

NSE: RUBICON | BSE: 544578 | ASM

Expensive Performer

Download real time

1386.30 6.70 (0.49%)

266.7K NSE+BSE Volume

NSE 08 Jul, 2026 3:31 PM (IST)

22,927

Market Cap

High in industry

Rubicon Research Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for RUBICON, BSE:544578 Rubicon Research Ltd.

Search Inside the pdf :

Rubicon Research Ltd.

30 May 2026

1386.30

0.49%

Another quarter, another beat: The compounder delivers

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) delivered another outstanding quarter, beating revenue, EBITDA, and PAT estimates by 4%, 11%, and 15%, respectively.

Rubicon Research has gained 100.07% in the last 6 Months

Rubicon Research Ltd.

15 Apr 2026

1386.30

0.49%

Arinna acquisition: Unlocking distribution moat and domestic growth engine

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) aims to make inroads into the central nervous system (CNS) therapy in India’s branded market (DF) through Arinna Lifescience (Arinna).

Number of FII/FPI investors decreased from 65 to 56 in Mar 2026 qtr

Rubicon Research Ltd.

18 Nov 2025

1386.30

0.49%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 15.28% in the last 1 Month

Rubicon Research Ltd.

13 Nov 2025

1386.30

0.49%

Outperformance across metrics; stellar start to the post-IPO phase

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. has an average target of 1160.00 from 5 brokers.

Rubicon Research Ltd.

13 Nov 2025

1386.30

0.49%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 185.84% in the last 1 Year

Rubicon Research Ltd.

13 Nov 2025

1386.30

0.49%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 78.03% in the last 3 Months

Rubicon Research Ltd.

13 Nov 2025

1386.30

0.49%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. is trading above all available SMAs

Rubicon Research Ltd.

13 Nov 2025

1386.30

0.49%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 78.03% in the last 3 Months

Rubicon Research Ltd.

13 Nov 2025

1386.30

0.49%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. is trading above all available SMAs

Rubicon Research Ltd.

31 Oct 2025

1386.30

0.49%

Gains in the gale

Buy: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research is a fast-growing research and development-driven pharmaceutical manufacturing company with a focus on regulated markets (particularly the US).